About 20 results found for searched term "CBP-IN-1" (0.157 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M21109 | Inobrodib | Epigenetic Reader Domain |
| CCS1477; CBP-IN-1; CBP/p300-IN-4 | ||
| Inobrodib (CCS1477, CBP-IN-1) is an orally active, potent and selective p300/CBP inhibitor. inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM and has a 170/130 fold selectivity compared to BRD4 with a Kd of 222 nM. Inobrodib (CCS1477) acts by inhibiting the expression and function of androgen receptor (AR) and by inhibiting c-Myc. | ||
| M41660 | CBP-IN-1 | Epigenetic Reader Domain |
| CBP-IN-1 is a potent CBP inhibitor, with an IC50 of 1.5 nM. | ||
| M56043 | CBP/p300-IN-1 | Epigenetic Reader Domain |
| CBP/p300-IN-1 is a CBP/EP300 bromodomain inhibitor. | ||
| M9141 | SGC-CBP30 | Epigenetic Reader Domain |
| Sgc-cbp30 is a potent and highly selective CBP/ P300 bromine domain inhibitor (Kd of 21 nM and 32 nM against CBP and P300, respectively), which is 40 times more selective than BRD4 [BRD4(1)]. Sgc-cbp30 strongly reduces the secretion of IL-17A in Th17 cells and has anti-inflammatory effects. | ||
| M9152 | CPI-637 | Epigenetic Reader Domain |
| CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. | ||
| M9561 | A-485 | Histone Acetyltransferase |
| A-485 is a potent and selective HAT inhibitor of p300/CBP in vitro with an IC50 of 10 nM in a p300 TR-FRET assay and 3 nM in a CBP TR-FRET assay with selectivity > 1000-fold over closely related HATs. | ||
| M10822 | GNE-781 | Epigenetic Reader Domain |
| GNE-781 (compound 19) is a highly potent, orally active, selective bromodomain inhibitor against cyclic adenosine monophosphate response element binding protein (CBP). The IC50 value is 0.94 nM (in TR-FRET assay). GNE-781 also suppresses BRET and BRD4(1), with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 has antitumor activity. | ||
| M13820 | GNE-049 | Epigenetic Reader Domain |
| GNE-049 is a highly potent and selective CBP inhibitor with an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also inhibits BRET and BRD4(1) with IC50s of 12 nM and 4200 nM, respectively. | ||
| M13823 | L-Moses | Epigenetic Reader Domain |
| L-45 | ||
| L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM. | ||
| M13824 | L-Moses dihydrochloride | Epigenetic Reader Domain |
| L-45 dihydrochloride | ||
| L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM. | ||
| M13826 | TPOP146 | Epigenetic Reader Domain |
| TPOP146 is a selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4. | ||
| M20613 | PF-CBP1 HCl | Epigenetic Reader Domain |
| PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively. | ||
| M25506 | DC-CPin711 | Epigenetic Reader Domain |
| DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC50 of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis. | ||
| M25513 | GNE-207 | Epigenetic Reader Domain |
| GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, exhibits a selectively index of >2500-fold against BRD4(1). GNE-207 shows excellent CBP potency, with an EC50 of 18 nM for MYC expression in MV-4-11 cells. | ||
| M25514 | GNE-272 | Epigenetic Reader Domain |
| GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50 values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300. | ||
| M25523 | Y08284 | Epigenetic Reader Domain |
| Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Y08284 has antitumor activity. | ||
| M25562 | TTK21 | Histone Acetyltransferase |
| TTK-21 | ||
| TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 can cross the blood-brain barrier, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has potential for research of brain neurogenesis and long-term memory function. | ||
| M30335 | DCH36_06 | Histone Acetyltransferase |
| DCH36_06 is a potent and selective p300/CBP inhibitor with IC50s of 0.6 μM and 3.2 μM for p300 and CBP, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity. | ||
| M56050 | CBP/p300-IN-5 | Histone Acetyltransferase |
| P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor, has an IC50 of 18.8 nM. | ||
| M56046 | ISOX-DUAL | Epigenetic Reader Domain |
| ISOX-DUAL is a dual CBP/BRD4 inhibitor with IC50 values of 0.65 μM and 1.5 μM for CBP and BRD4, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
